Amy Gamble is a research fellow in the Biostatistics, Evidence Synthesis, Test evaluation and prediction Models (BESTEAM) team, currently undertaking a range of evidence synthesis projects for the NIHR Warwick-Birmingham Screening ESG as required by the UK National Screening Committee (NSC) to inform national policy. Amy has considerable experience in undertaking a variety of review types, including systematic reviews, to support health technology assessments (HTA).